newsfilter
← Latest News
PR Newswire·

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

ARMP
  • FDA confirmed that safety and efficacy data from Armata's Phase 2a diSArm study support advancing AP-SA02 to a Phase 3 clinical trial.
  • Armata Pharmaceuticals becomes the first bacteriophage company to advance a clinical candidate to Phase 3.
  • The Phase 3 study will assess the superiority of intravenously administered AP-SA02 against the current standard of care for complicated Staphylococcus aureus bacteremia.
  • The Phase 3 study is anticipated to initiate in the second half of 2026.
  • FDA provided critical guidance on Phase 3 study design, Chemistry, Manufacturing, and Controls (CMC), and future Biologics License Application requirements.
  • Armata has submitted a request for Qualified Infectious Disease Product Designation (QIDP) for AP-SA02.
  • AP-SA02 is a fixed multi-phage cocktail designed to treat complicated bacteremia caused by both MSSA and MRSA strains.
  • The Phase 2a diSArm study results were previously announced in May 2025 with further presentation at IDWeek 2025.
  • The Phase 3 primary endpoint is expected to be clinical response at the end of best available antibiotic therapy (BAT) and 28 days later.
  • Phase 1b/2a clinical development was partially supported by a $26.2 million Department of Defense award.